Magical Mogrify at the double in Scrip awards
Mogrify, the Cambridge UK business aiming to transform the development of cell therapies, received MSD’s Innovation Award at the 15th Annual Scrip Awards while the Lifetime Achievement Award was presented to D. Jane Osbourn, who is chair of the company.
The Innovation Award recognises the significant potential the company’s direct cellular conversion technology has to disrupt the future development of new medicines. Dr Osbourn received the Lifetime Achievement Award in recognition of her outstanding contribution to the biotech industry throughout her career.
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform any human cell type into any other, without going through a pluripotent stem cell- or progenitor cell-state.
The company is using this platform to produce cell types with unrivaled safety, efficacy and scalable manufacturing profiles that can be used to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases.
Dr Osbourn is a scientific leader in the field of antibody engineering with more than 30 years of experience in biologics discovery and development. During this time she has been Vice President for Research and Development and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), chair of the BioIndustry Association, a director of Babraham Bioscience Technologies and a director of Cambridge Enterprise.
She has made significant contributions to the discovery and development of phage display technology, eight marketed drugs (including HUMIRA® and BENLYSTA®) and over 40 clinical candidates.
The Scrip Awards seek to applaud the role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span a range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. This year’s new category, MSD’s Innovation Award, acknowledges and celebrates the outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines. Scrip’s Lifetime Achievement Award is presented to individuals who have had a distinguished career in the biotech or pharmaceutical arena, primarily within industry with a consistent history of exceptional service, throughout their career.
Mogrify CEO, Dr Darrin Disley, said: “Our systematic approach to the discovery of novel cell conversions has the potential to transform cell therapy.
“Mogrify’s technology opens up the opportunity to develop and scale up any autologous and allogeneic cell therapies, as well as create a new class of therapies: in vivo reprograming and could therefore have a significant impact on the treatment of degenerative conditions and cancers. We are proud to have our innovative platform and pioneering approach recognised by the judges.
“Dr Osbourn has contributed significantly to the industry throughout her impressive career and is globally renowned for her expertise in biologics discovery and development. She is an inspirational leader and we look forward to celebrating her exceptional achievements.”
Dr Jane Osbourn added: “I am honoured to have received the Lifetime Achievement Award. Throughout my career I have been fortunate to have worked with many pioneering scientists, who have helped us achieve success in biologics discovery and development.
“Working together in a diverse team is vital if we are to build great culture and drive innovation. I would like to thank all the extraordinary people who have supported me and I hope to continue to foster many more successful collaborations.”
Professor Jose Polo, CMO (co-founder) and Prof. Julian Gough, CSO (co-founder) were presented with the Innovation Award at the London Hilton on Park Lane in Mayfair.